-
Circulating Low Absolute CD4+ T Cell Counts May Predict Poor Prognosis in Extranodal NK/T-Cell Lymphoma Patients Treating with Pegaspargase-Based Chemotherapy
-
Ya-Ping Zhang, Run Zhang, Hua-Yuan Zhu, Li Wang, Yu-Jie Wu, Jin-Hua Liang, Wen-Yu Shi, Hong Liu, Wei Xu, Jian-Yong Li
-
Cancer Res Treat. 2019;51(1):368-377. Published online May 14, 2018
-
DOI: https://doi.org/10.4143/crt.2018.010
-
-
Abstract
PDFPubReaderePub
- Purpose
Extranodal natural killer/T-cell lymphoma, nasal type (ENKTL) is a rare subtype of non-Hodgkin lymphoma, and asparaginase-based regimens are the best first-line treatments. Data on the role of specific circulating lymphocyte subsets in the progression of ENKTL are limited. The aim of this study was to investigate the clinical correlation and distribution of circulating absolute CD4+ T-cell counts (ACD4Cs) in ENKTL.
Materials and Methods
We retrospectively searched medical records for 70 newly diagnosed ENKTL patients treated with pegaspargase-based regimens. Comparison of ACD4Cs as a continuous parameter in different groups was calculated. Univariate and multivariate analyses were used to assess prognostic factors for overall survival (OS) and progression-free survival (PFS).
Results
Stage III/IV, B symptoms, elevated lactate dehydrogenase, monocytopenia, high-intermediate and high risk International Prognostic Index (IPI) and Korean Prognostic Index (KPI), high risk Prognostic Index of Natural Killer Lymphoma (PINK), and lower lymphocytes were significantly associated with low ACD4C at diagnosis. With a median follow-up time of 32 months, patients who had an ACD4C < 0.30×109/L had a worse OS. Median OS was 11 months and median PFS was 5 months in the low ACD4C cohort. There were significant differences in both OS and PFS between the two cohorts. Moreover, multivariate Cox analysis identified ACD4Cs as an independent predictor for OS and PFS.
Conclusion
Low ACD4Cs were associated with poorer survival and could act as a negative predictor for ENKTL patients treated with asparaginase-based regimens.
-
Citations
Citations to this article as recorded by
- Identification and validation of ubiquitin-proteasome system related genes as a prognostic signature for papillary renal cell carcinoma
Xin Zhang, Xinli Liu, Renhua Xiong, Han-Xiang An Aging.2022;[Epub] CrossRef - An Immune-Clinical Prognostic Index (ICPI) for Patients With De Novo Follicular Lymphoma Treated With R-CHOP/CHOP Chemotherapy
Yaxiao Lu, Jingwei Yu, Wenchen Gong, Liping Su, Xiuhua Sun, Ou Bai, Hui Zhou, Xue Guan, Tingting Zhang, Lanfang Li, Lihua Qiu, Zhengzi Qian, Shiyong Zhou, Bin Meng, Xiubao Ren, Xianhuo Wang, Huilai Zhang Frontiers in Oncology.2021;[Epub] CrossRef - Towards Next Generation Biomarkers in Natural Killer/T-Cell Lymphoma
Jason Yongsheng Chan, Jing Quan Lim, Choon Kiat Ong Life.2021; 11(8): 838. CrossRef - The predictive value of dynamic monitoring of peripheral blood lymphocyte to monocyte ratio in patients with extranodal NK/T cell lymphoma
Shengnan Zhang, Mengjuan Li, Fangfang Yuan, Lin Chen, Ruihua Mi, Xudong Wei, Yongping Song, Qingsong Yin Cancer Cell International.2019;[Epub] CrossRef - It’s all about the CD3+ T-cells: how circulating immune cell subset analyses can predict early relapse in Hodgkin lymphoma
Jonathan Moreira, Leonidas C. Platanias, Kehinde U. A. Adekola Leukemia & Lymphoma.2019; 60(10): 2345. CrossRef - The combined prognostic value of pretreatment neutrophil-to-lymphocyte ratio, lymphocyte-to-monocyte ratio, and platelet-to-lymphocyte ratio in stage IE/IIE extranodal natural killer/T-cell lymphoma
Xiaoying Quan Oncology and Translational Medicine.2019; : 137. CrossRef
-
8,142
View
-
217
Download
-
7
Web of Science
-
6
Crossref
|